Abera Bioscience develops mucosal vaccines on its proprietary BERA outer membrane vesicle platform. The company originated as a spin-out from Stockholm University and Vrije Universiteit Amsterdam. Its BERA platform displays antigens at the surface of outer membrane vesicles, where a modular coupling system attaches antigens in a plug-and-play manner, and the resulting vaccines are produced using established microbial processes.
Its intranasal candidate Ab-01.12 targets conserved protein antigens on outer membrane vesicles for serotype-independent pneumococcal protection, while an intranasal influenza candidate presents HA antigens at high density on the vesicles for rapid antigen updating, and an early-stage tuberculosis program explores key antigens. The company works with academic groups, industry partners, contract development and manufacturing organizations, and global health organizations.
